Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 137.54 -1.35 (-0.97%) Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 966,558 Open 138.07 Bid (Size) 137.56 (3) Ask (Size) 144.82 (3) Prev. Close 138.89 Today's Range 137.34 - 140.47 52wk Range 93.02 - 148.37 Shares Outstanding 98,700,000 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Sarepta Therapeutics Stock Shows Improved Technical Strength April 29, 2024 The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. Via Investor's Business Daily Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review April 26, 2024 Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. Via Investor's Business Daily Performance YTD +4.41% +4.41% 1 Month -2.72% -2.72% 3 Month -3.18% -3.18% 6 Month +23.98% +23.98% 1 Year +32.22% +32.22% More News Read More 3 Red-Hot Biotech Rockets Blasting Off in 2024 April 24, 2024 Via InvestorPlace Topics Economy Exposures Economy Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase. April 11, 2024 Via Chartmill Where Neurocrine Biosciences Stands With Analysts April 10, 2024 Via Benzinga NASDAQ:NBIX is not too expensive for the growth it is showing. March 20, 2024 Via Chartmill Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. March 20, 2024 Via Chartmill Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder April 23, 2024 Via Benzinga No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win April 23, 2024 Via Investor's Business Daily Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides April 16, 2024 From Sentia Medical Sciences, Inc. Via GlobeNewswire The 5 Stocks Most Sold By Insiders This Year April 16, 2024 Via MarketBeat Why Quality-Oriented Investors Should Consider NASDAQ:NBIX. March 15, 2024 Via Chartmill Decoding 8 Analyst Evaluations For Neurocrine Biosciences March 13, 2024 Via Benzinga Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock? February 28, 2024 Via Chartmill For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. April 10, 2024 Via Chartmill Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag. April 05, 2024 Via Chartmill S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind March 23, 2024 Via Investor's Business Daily Topics Economy Stocks Exposures Interest Rates US Equities Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform March 19, 2024 Via Benzinga Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark March 18, 2024 Via Investor's Business Daily AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base March 16, 2024 Via Investor's Business Daily Topics Artificial Intelligence Exposures Artificial Intelligence NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying. March 14, 2024 Via Chartmill In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences March 13, 2024 Via Benzinga 3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success March 06, 2024 Via InvestorPlace Amicus Therapeutics Stock Sees RS Rating Improve To 74 March 05, 2024 Via Investor's Business Daily Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. February 28, 2024 Via Chartmill Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
